Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense?

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 11, 2013, Pages 1249-1261

  Amodeo, Valeria ^a   Bazan, Viviana ^a   Fanale, Daniele ^a   Insalaco, Lavinia ^a   Caruso, Stefano ^a   Cicero, Giuseppe ^a   Bronte, Giuseppe ^a   Rolfo, Christian ^b   Santini, Daniele ^c   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Anti miR 182; Colon cancer; Egr 1; Sp 1; Thrombospondin 1

Indexed keywords

AMBION; MICRORNA; MICRORNA 182; MICRORNA 182 ANTIBODY; RNA ANTIBODY; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR EGR 1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL STRAIN HCT116; COLON CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

BASE SEQUENCE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; THROMBOSPONDIN 1;

EID: 84886939759     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.832206     Document Type: Article

References (60)

1. Zavoral M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-15
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46(4):765-81
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71-96
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
6. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-19
7. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004;5(7):522-31
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
9. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008;14(1):1-6
10. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15(2):261-71
11. Hua Z, Lv Q, Ye W, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 2006;1:e116
12. Cascio S, D'Andrea A, Ferla R, et al. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 2010;224(1):242-9
13. Dews M, Fox JL, Hultine S, et al. The myc-miR-17 ~ 92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res 2010;70(20):8233-46
14. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765(2):178-88
15. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995;130(3):503-6
16. Ferrari do Outeiro-Bernstein MA, Nunes SS, Andrade AC, et al. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan. Matrix Biol 2002; 21(4): 311-24
17. Isenberg JS, Annis DS, Pendrak ML, et al. Differential interactions of thrombospondin-1,-2, and-4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284(2):1116-25
18. Isenberg JS, Ridnour LA, Perruccio EM, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005;102(37):13141-6
19. Isenberg JS, Romeo MJ, Yu C, et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 2008;111(2):613-23
20. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 2006;71(4):785-93
21. Ramanathan S, Mazzalupo S, Boitano S, Montfort WR. Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration. Biochemistry 2011;50(36):7787-99
22. Isenberg JS, Ridnour LA, Dimitry J, et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281(36):26069-80
23. Panchatcharam M, Miriyala S, Yang F, et al. Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. Int J Biochem Cell Biol 2010;42(6):965-74
24. Isenberg JS, Calzada MJ, Zhou L, et al. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol 2005;24(2):110-23
25. Isenberg JS, Romeo MJ, Abu-Asab M, et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res 2007;100(5):712-20
26. Isenberg JS, Hyodo F, Matsumoto K, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 2007;109(5):1945-52
27. Stenina OI, Plow EF. Counterbalancing forces: what is thrombospondin-1 doing in atherosclerotic lesions? Circ Res 2008;103(10):1053-5
28. Milkiewicz M, Hudlicka O, Brown MD, Silgram H. Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 2005;289(1):H336-43
29. Greenaway J, Lawler J, Moorehead R, et al. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 2007;210(3):807-18
30. Gupta K, Gupta P, Wild R, et al. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999;3(2):147-58
31. Zhang X, Kazerounian S, Duquette M, et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 2009;23(10):3368-76
32. Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285(50):38923-32
33. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6(1):41-8
34. Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138(3):707-17
35. Short SM, Derrien A, Narsimhan RP, et al. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 2005;168(4):643-53
36. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005;128(6 Suppl):585S-90S
37. Young GD, Murphy-Ullrich JE. Molecular interactions that confer latency to transforming growth factor-beta. J Biol Chem 2004;279(36):38032-9
38. Donoviel DB, Framson P, Eldridge CF, et al. Structural analysis and expression of the human thrombospondin gene promoter. J Biol Chem 1988;263(35):18590-3
39. Zhao HY, Ooyama A, Yamamoto M, et al. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res 2008;68(17):7035-41
40. Okamoto M, Ono M, Uchiumi T, et al. Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells-transcriptional activation and messenger RNA stabilization. Biochim Biophys Acta 2002;1574(1):24-34
41. Huang RP, Fan Y, Ni Z, et al. Reciprocal modulation between Sp1 and Egr-1. J Cell Biochem 1997;66(4):489-99
42. Zhao HY, Ooyama A, Yamamoto M, et al. Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. Cancer Lett 2008;270(1):156-63
43. van Almen GC, Verhesen W, van Leeuwen RE, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011;10(5):769-79
44. Sundaram P, Hultine S, Smith LM, et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res 2011;71(24):7490-501
45. Stenvang J, Petri A, Lindow M, et al. Inhibition of microRNA function by anti-miR oligonucleotides. Silence 2012;3(1):1
46. Cekaite L, Rantala JK, Bruun J, et al. MiR-9,-31, and-182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012;14(9):868-79
47. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36(12):4158-71
48. Sarver AL, French AJ, Borralho PM, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009;9:401
49. Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353(9150):391-9
50. Huynh C, Segura MF, Gaziel-Sovran A, et al. Efficient in vivo microRNA targeting of liver metastasis. Oncogene 2011;30(12):1481-8
51. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989;96(3):736-49
52. Maeda K, Nishiguchi Y, Kang SM, et al. Expression of thrombospondin-1 inversely correlated with tumor vascularity and hematogenous metastasis in colon cancer. Oncol Rep 2001;8(4):763-6
53. Maeda K, Nishiguchi Y, Yashiro M, et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000;5(4):373-8
54. Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res 2007;74(2-3):90-9
55. Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 2010;70(23):9570-80
56. Kaur S, Roberts DD. CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2. Cell Cycle 2011;10(1):10-12
57. Frazier WA, Gao AG, Dimitry J, et al. The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J Biol Chem 1999;274(13):8554-60
58. Isenberg JS, Pappan LK, Romeo MJ, et al. Blockade of thrombospondin-1- CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg 2008;247(1):180-90
59. Nicoloso MS, Spizzo R, Shimizu M, et al. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009;9(4):293-302
60. Henkin J, Volpert OV. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin Ther Targets 2011;15(12):1369-86